These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 623119)

  • 21. Effects of oral adenosine 5'-triphosphate and adenosine in enteric-coated capsules on indomethacin-induced permeability changes in the human small intestine: a randomized cross-over study.
    Bours MJ; Bos HJ; Meddings JB; Brummer RJ; van den Brandt PA; Dagnelie PC
    BMC Gastroenterol; 2007 Jun; 7():23. PubMed ID: 17578566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluoride metabolism in patients with chronic renal failure.
    Spencer H; Kramer L; Gatza C; Norris C; Wiatrowski E; Gandhi VC
    Arch Intern Med; 1980 Oct; 140(10):1331-5. PubMed ID: 7425768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aluminium hydroxide gels and intestinal phosphorus absorption.
    Bingham S; Rose GA
    J Hum Nutr; 1977 Feb; 31(1):5-10. PubMed ID: 874318
    [No Abstract]   [Full Text] [Related]  

  • 24. [Antacid action of the aluminum cation: comparison of the in vitro effect of hydroxide and phosphate in open and closed systems].
    Vatier J; Lionnet F; Vitre MT
    Gastroenterol Clin Biol; 1987 Nov; 11(11):758-63. PubMed ID: 3428519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of intestinal phosphate binders in patients maintained by hemodialysis.
    Johnson WJ; O'Brien PC
    Nephron; 1978; 21(3):123-30. PubMed ID: 673095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.
    Coyne D; Acharya M; Qiu P; Abboud H; Batlle D; Rosansky S; Fadem S; Levine B; Williams L; Andress DL; Sprague SM
    Am J Kidney Dis; 2006 Feb; 47(2):263-76. PubMed ID: 16431255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Kinetics of aluminum absorption and serum concentration in chronic renal insufficiency].
    Sárszegi Z; Jobst K; Nagy J
    Orv Hetil; 2000 Aug; 141(35):1915-7. PubMed ID: 11019592
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of aluminum hydroxide on iron absorption.
    Rastogi SP; Padilla F; Boyd CM
    J Ark Med Soc; 1976 Aug; 73(3):133-4. PubMed ID: 134015
    [No Abstract]   [Full Text] [Related]  

  • 29. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide.
    Coburn JW; Mischel MG; Goodman WG; Salusky IB
    Am J Kidney Dis; 1991 Jun; 17(6):708-11. PubMed ID: 2042654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of small doses of aluminum-containing antacids on calcium and phosphorus metabolism.
    Spencer H; Kramer L; Norris C; Osis D
    Am J Clin Nutr; 1982 Jul; 36(1):32-40. PubMed ID: 7091034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ranitidine suppresses aluminium absorption in man.
    Rodger RS; Muralikrishna GS; Halls DJ; Henderson JB; Forrest JA; Macdougall AI; Fell GS
    Clin Sci (Lond); 1991 May; 80(5):505-8. PubMed ID: 1851692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of a new phosphate binder in chronic renal insufficiency.
    Rutherford E; King S; Perry B; Blondin J; Finley T; Mason N; Sparks R; Slatopolsky E
    Kidney Int; 1980 Apr; 17(4):528-34. PubMed ID: 7392426
    [No Abstract]   [Full Text] [Related]  

  • 33. Phosphate-binding properties and electrolyte content of aluminum hydroxide antacids.
    Balasa RW; Murray RL; Kondelis NP; Bischel MD
    Nephron; 1987; 45(1):16-21. PubMed ID: 3808143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of calcium acetate or calcium citrate on intestinal aluminum absorption.
    Nolan CR; Califano JR; Butzin CA
    Kidney Int; 1990 Nov; 38(5):937-41. PubMed ID: 2266679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of aluminum hydroxide gel on quinidine gluconate absorption.
    Mauro VF; Mauro LS; Fraker TD; Temesy-Armos PN; Somani P
    DICP; 1990 Mar; 24(3):252-4. PubMed ID: 2316233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of oral bases on aluminum absorption.
    Mauro LS; Kuhl DA; Kirchhoff JR; Mauro VF; Hamilton RW
    Am J Ther; 2001; 8(1):21-5. PubMed ID: 11304654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The absorption of dietary phosphorus and calcium in hemodialysis patients.
    Ramirez JA; Emmett M; White MG; Fathi N; Santa Ana CA; Morawski SG; Fordtran JS
    Kidney Int; 1986 Nov; 30(5):753-9. PubMed ID: 3784305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The bioavailability of flufenamic acid from aluminum flufenamate tablet and flufenamic acid capsule, and the influence of food and aluminum hydroxide gel.
    Kaniwa N; Ogata H; Aoyagi N; Ejima A
    J Pharmacobiodyn; 1982 Mar; 5(3):187-92. PubMed ID: 7097486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mineral-metabolic side effects of low-dose antacids.
    Weberg R; Berstad A; Aaseth J; Falch JA
    Scand J Gastroenterol; 1985 Aug; 20(6):741-6. PubMed ID: 4035293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of aluminum hydroxide timing administration in relation to meals in controlling hyperphosphatemia in dialysis patients.
    Katopodis KP; Andrikos E; Pappas M; Siamopoulos KC
    Int J Artif Organs; 2005 Aug; 28(8):803-7. PubMed ID: 16211530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.